Loading…
Glenmark Pharmaceuticals (GLENMARK)₹2,671+2.94%Pharmaceuticals
Glenmark Pharmaceuticals is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 42.0 against a peer median of 39.2, and ROCE of 40.1% against a peer median of 15.0%, and latest-quarter sales growth of 23.2% against a peer median of 16.4%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories | 1,15,648 | 41.2 | 13.0 | 11.2 | 0.19 | 0.6 | 33,781 | 4,160 | −1.4 | −31.7 | vs GLENMARK |
| Cipla | 1,13,427 | 39.2 | 15.0 | 11.7 | 0.02 | 0.9 | 28,258 | 3,871 | −2.5 | −37.1 | vs GLENMARK |
| Mankind Pharma | 1,10,201 | 49.0 | 14.0 | 13.1 | 0.31 | 0.0 | 14,271 | 1,942 | 17.4 | 37.7 | vs GLENMARK |
| Aurobindo Pharma | 1,07,793 | 29.0 | 13.0 | 10.2 | 0.21 | 0.0 | 33,715 | 3,490 | 16.4 | 25.2 | vs GLENMARK |
| Lupin | 92,543 | 16.7 | 29.9 | 28.7 | 0.29 | 0.9 | 28,016 | 5,347 | 32.1 | 16.2 | vs GLENMARK |
| Glenmark Pharmaceuticals | 75,325 | 42.0 | 40.1 | 30.5 | 0.06 | 0.1 | 16,989 | 1,362 | 23.2 | 927.6 | — |
| Alkem Laboratories | 64,547 | 29.9 | 21.0 | 18.8 | 0.15 | 1.0 | 14,712 | 2,360 | 11.0 | −22.0 | vs GLENMARK |
| Biocon | 60,066 | 108.4 | 4.0 | 1.4 | 0.45 | 0.1 | 16,993 | 369 | 10.0 | 54.0 | vs GLENMARK |
| Abbott India | 56,562 | 36.6 | 45.1 | 34.4 | 0.04 | 2.0 | 6,909 | 1,554 | 6.4 | 7.6 | vs GLENMARK |
| Gland Pharma | 54,490 | 48.4 | 15.0 | 10.7 | 0.03 | 0.6 | 6,440 | 1,026 | 19.7 | 47.5 | vs GLENMARK |
| IPCA Laboratories | 49,726 | 38.0 | 17.1 | 15.7 | 0.10 | 0.3 | 9,591 | 1,186 | 20.7 | 82.0 | vs GLENMARK |
| Peer median | 75,325 | 39.2 | 15.0 | 13.1 | 0.15 | 0.6 | 16,989 | 1,942 | 16.4 | 25.2 |
Listed companies closest to Glenmark Pharmaceuticals in Pharmaceuticals include Dr. Reddy's Laboratories, Cipla, Mankind Pharma, Aurobindo Pharma, Lupin, Alkem Laboratories, Biocon, Abbott India.
Dr. Reddy's Laboratories, with a market cap of ₹1.16 L Cr.
Glenmark Pharmaceuticals trades at a P/E of 42.0; the median of its peer set is 39.2. A P/E above or below the median is a description, not a judgement on value.
Glenmark Pharmaceuticals' return on capital employed is 40.1%, above the peer median of 15.0%.